Therapy with a variety of antimicrobial agents has been shown to produce changes in the normal fecal microflora (2, 14) . Although the role of the normal flora is still poorly understood, there is evidence that alterations in flora may have important consequences.
Cefoperazone is a new agent of the cephalosporin class which, because it is active against a very broad spectrum of microorganisms (7) and is excreted in large part via the biliary tract (10) , might be expected to produce appreciable changes in the intestinal flora. Thus, we evaluated the effects of parenteral cefoperazone therapy upon human fecal flora.
MATERIALS AND METHODS
Four hospitalized, adult male patients with soft tissue or bone infections for which parenteral cefoperazone was judged to be appropriate therapy were chosen to have total fecal flora studies performed. Although each patient had received antimicrobial agents in the past, no antimicrobial therapy had been given in the preceding 2 weeks. All received cefoperazone, 4 g daily, for 12 to 30 days. Written, informed consent was obtained from each patient.
Fecal specimens from all patients were collected before therapy and on day 8 of therapy. In addition, for patient 1, fecal specimens were collected on day 22 of therapy and at 3 weeks after cessation of cefoperazone. Specimens were collected in nonsterile plastic containers and were transported immediately to an anaerobic chamber in which they were processed. Approximately 1 g of homogenized specimen was weighed, diluted 10-fold in 0.5% yeast extract solution containing glass beads, and emulsified in a Vortex mixer. Serial 10-fold dilutions were made in yeast extract, and volumes of 0.1 ml of selected dilutions (the lowest dilution being 1:10) were plated by a rotator-pipette method onto the following media for aerobic incubation: brucella blood agar (Difco Laboratories, Detroit, Mich.) with 5% sheep blood supplemented with vitamin K1 and hemin (BAK) (13); mannitol-salt agar (Clinical Standards Laboratories, Carson, Calif.); MacConkey agar (Clinical Standards Laboratories); Pfizer selective enterococcus agar (Pfizer Diagnostics Div., New York, N.Y.); cetrimide agar (Eastman Kodak Co., Rochester, N.Y.); and Sabouraud agar (Difco) with chloramphenicol. The following media were inoculated for anaerobic incubation: BAK, Bacteroides-bile-esculin agar, kanamycin-vancomycin-laked-blood agar, rifampin-blood agar, Bifidobacterium agar, cycloserine-cefoxitin-egg yolkfructose agar, and egg yolk-neomycin agar (for ethanol-treated dilutions) as described previously (13 Fecal cultures for C. difficile and assays for cytotoxin (performed one to four times per patient) were negative for all patients during therapy. However, patients 1, 2, and 4 acquired C. difficile (at 3 weeks, 2 months, and 5 weeks, respectively) after discontinuation of cefoperazone. Two of these patients, 1 and 2, while receiving subsequent cephalosporin therapy, had diarrhea, with fecal cultures positive for C. difficile (not quantitated for patient 1; counts of 5 loglo for patient 2) but with negative fecal cytotoxin assays. After all antimicrobial therapy was stopped, their symptoms resolved, and C. dificile was no longer detected in their feces. Patient 4 did not receive additional antimicrobial therapy, and his acquisition of C. difficile (with counts of 6 log1o per g of feces [wet weight]; negative fecal cytotoxin assay) was not associated with symptoms.
Concentrations of cefoperazone in the feces of our patients during therapy were extremely high, ranging from 10.7 to 21.7 mg/g offeces (dry weight) ( Table 1) . DISCUSSION The alterations in fecal flora which we observed in our cefoperazone-treated patients are the most marked that have been reported in association with the use of a single antimicrobial agent. However, the significance of changes in intestinal microecology is not yet fully understood, and conclusions as to clinical importance cannot be drawn from our study of a small number of patients. Although it is possible that the marked alter-either a potential therapeutic agent for the eradiations in fecal flora contributed to the diarrhea cation of C. difficile (as occurred in one of our noted by our patients (for example, by altering patients) or, alternatively, as an agent predisposbacterial metabolism of bile acids), there are ing to the development of C. difficile-induced other possible mechanisms for this symptom, disease after discontinuation of therapy are insuch as direct stimulation of intestinal smooth teresting considerations which merit further inmuscle (reported by Takai et al. to occur in vestigation. Asymptomatic acquisition of C. difexperimental animals with concentrations of ce-ficile after antimicrobial therapy has been foperazone comparable to those found in the recognized recently as not uncommon (17) . Adfeces of our patients [15] ) or changes in intestinal ditional studies are needed to identify the factors water transport (such as those which have been which differentiate asymptomatic colonization reported in association with other antimicrobial from disease production by C. difficile.
therapy [4] ).
We cannot explain the high incidence of diar-
We found no evidence that C. difficile is a rhea observed in our patients. One patient (pacause of diarrhea during cefoperazone therapy. tient 3) had such mild symptoms that his change However, the possible roles of cefoperazone as in bowel habits would not have been noticed without specific inquiry. Two patients had histories of excessive alcohol intake for many years, and another had long-standing diabetes mellitus with diabetic gastropathy. Perhaps these underlying conditions or the relatively long courses of therapy given to our patients contributed to their developing diarrhea. Alternatively, this symptom may be a more common side effect of cefoperazone therapy than is appreciated, noted in our study because of the special interest in the gastrointestinal tract. Except for patient 1, who had multiple evaluations for a variety of enteric pathogens, patients were not evaluated for intestinal pathogens other than C. difficile. However, the prompt resolution of diarrhea after discontinuation of cefoperazone for the three patients other than patient 1 suggests a causal relationship, whatever the mechanism.
In addition to the local effects on gastrointestinal physiology which may occur with antimicrobial therapy, there are other potentially important consequences which may result from alterations of the intestinal flora. For example, there is evidence that the normal flora may act as a natural defense (often termed "colonization resistance" [16] ) against infection with enteric pathogens such as Salmonella spp. and Shigella spp. (5) as well as provide protection against antimicrobial agent-associated colitis caused by C. difficile (1) . In addition, members of the intestinal microflora attain importance when they serve as a reservoir of potential pathogens (11) ; thus, antimicrobial agent-induced colonization of the bowel by resistant bacteria and fungi may predispose patients to subsequent endogenous infections with these organisms (11, 12, 18) . It is of interest that in addition to acquiring resistant microorganisms, three of our patients had intestinal colonization with cefoperazonesusceptible Pseudomonas sp. during therapy.
Another role of the intestinal flora, that of synthesizing vitamin K, may be affected adversely by antimicrobial agent-induced changes (2). Thus, although our patients had no bleeding problems or abnormal clotting studies, the potential for bleeding diatheses in patients with marked alterations in flora should be considered.
In contrast, there are clinical settings, such as preparation for intestinal surgery and "intestinal decontamination" for severely neutropenic patients, in which suppression of the intestinal flora is indicated. Whether retention of anaerobic flora is desirable in these situations (to maintain colonization resistance) is not certain. Perhaps cefoperazone should be evaluated in these conditions.
Clinicians should be aware of the marked changes in intestinal flora which may accompany the use of cefoperazone, considering, for example, that in patients who develop infection during or immediately after therapy, Pseudomonas spp. or Candida spp. may be likely pathogens. In addition, there is the opportunity and need to evaluate which, if any, of the many possible consequences attend the temporary marked suppression of the normal flora. Clearly, further study is needed to define properly the role of the normal flora and the importance of alterations in intestinal microecology.
